A Phase 1 Multi-center, Open-label Dose Escalation and Expansion Study of PCA062 Administered Intravenously in Adult Patients With p-CAD Positive Tumors
Phase of Trial: Phase I
Latest Information Update: 20 Nov 2017
At a glance
- Drugs PCA 062 (Primary)
- Indications Breast cancer; Head and neck cancer; Oesophageal cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Novartis Pharmaceuticals
- 18 Jul 2017 Planned End Date changed from 25 Jun 2018 to 25 Dec 2018.
- 18 Jul 2017 Planned primary completion date changed from 15 Jun 2017 to 14 Jun 2018.
- 17 Apr 2017 Planned number of patients changed from 75 to 90.